Advertisement

Journal of Cancer Research and Clinical Oncology

, Volume 144, Issue 11, pp 2177–2186 | Cite as

Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China

  • Yiran Zhang
  • Meng Zhang
  • Yifei Jiang
  • Xiulian Li
  • Yanli He
  • Pengjiao Zeng
  • Zhihua Guo
  • Yajing Chang
  • Heng Luo
  • Yong Liu
  • Cui Hao
  • Hua Wang
  • Guoqing Zhang
  • Lijuan Zhang
Review – Clinical Oncology
  • 155 Downloads

Abstract

Purpose

Lentinan is a polysaccharide extracted from Shiitake mushrooms that have been used to improve general health for thousands of years in Asia. Lentinan injection is a clinically approved drug in several countries in Asia. The purpose of this study is to review the structure, preclinical and clinical studies, and molecular mechanisms of lentinan. Most importantly, the clinical effectiveness of lentinan as an adjuvant therapeutic drug in treating patients with lung cancer in China during the past 12 years is analyzed statistically.

Methods

We carried out literature search of randomized controlled trials (RCTs) published from 2004 to 2016 based on CNKI (China National Knowledge Infrastructure), VIP (Chongqing VIP Chinese Scientific Journals Database) and Wanfang database, and 38 eligible RCTs of lentinan-associated lung cancer treatment were identified, containing 3,117 patients.

Results

The structure and function relationship and underlying molecular mechanism of lentinan as an immunostimulant has been summarized. The mean value of overall response rate in treating lung cancer was increased from 43.3% of chemotherapy alone to 56.9% of lentinan plus chemotherapy [p < 0.001, 95% confidence interval (CI) 0.102–0.170]. Compared with chemotherapy alone, lentinan plus chemotherapy showed more efficacy in treating lung cancer (pooled RR 0.79, 95% CI 0.74–0.85) and no statistical heterogeneity was found among studies (I2 = 11%).

Conclusion

Clinical data presented in the past 12 years shows that lentinan is effective not only in improving quality of life, but also in promoting the efficacy of chemotherapy during lung cancer treatment.

Keywords

Cancer Chemotherapy Immunobalance Immunostimulant Lentinan 

Notes

Acknowledgements

The authors thank Alexander Lu of St. Louis University for language editing of the entire manuscript.

Funding

This research was supported by National Natural Science Foundation of China (Grant nos. 91129706, 81672585); Key Technology Fund of Shandong Province (Grant 2016ZDJS07A07); the “Double First-Class” fund of Shandong Province; Taishan Scholar Fellowship (05052011) and Postdoctoral application research project in Qingdao, China (Grant 40518060042).

Compliance with ethical standards

Conflict of interest

Authors declare no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. Bai R (2010) Radiation and chemotherapy combined with lentinan to treat with non-small cell lung cancer with brain metastasis. Hebei Med J 32:2046–2047Google Scholar
  2. Banin Hirata BK, Oda JMM, Losi Guembarovski R et al (2014) Molecular markers for breast cancer: prediction on tumor behavior. Dis Mark 2014:1–12CrossRefGoogle Scholar
  3. Bao L, Wang Y, Ma R et al (2015) Apoptosis-inducing effects of lentinan on the proliferation of human bladder cancer T24 cells. Pak J Pharm Sci 28:1595–1600PubMedGoogle Scholar
  4. Barrett SV (2010) Breast cancer. J R Coll Physicians Edinb 40:335–339CrossRefGoogle Scholar
  5. Bekkering S, Blok BA, Joosten LA et al (2016) In vitro experimental model of trained innate immunity in human primary monocytes. Clin Vaccine Immunol 23:926–933CrossRefGoogle Scholar
  6. Brown GD, Gordon S (2003) Fungal beta-glucans and mammalian immunity. Immunity 19:311–315CrossRefGoogle Scholar
  7. Carter P (2001) Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1:118–129CrossRefGoogle Scholar
  8. Chai M, Xiao Y (2005) Effect of lentinan in the treatment of advanced non-small cell lung cancer. J Med Forum 26:69–70Google Scholar
  9. Chang X, Shao P, Huang X et al (2013) Clinical research on cisplatin combined lentinan in local therapy of malignant pleural effusion. New Med 44:840–842Google Scholar
  10. Chen J, Raymond K (2008) Beta-glucans in the treatment of diabetes and associated cardiovascular risks. Vasc Health Risk Manag 4:1265–1272CrossRefGoogle Scholar
  11. Chen J, Seviour R (2007) Medicinal importance of fungal β-(1 → 3), (1 → 6)-glucans. Mycol Res 111:635–652CrossRefGoogle Scholar
  12. Chen Q, Peng H, Dong L et al (2016) Activation of the NRF2-ARE signalling pathway by the Lentinula edodes polysaccharose LNT alleviates ROS-mediated cisplatin nephrotoxicity. Int immunopharmacol 36:1–8CrossRefGoogle Scholar
  13. Cheng SC, Quintin J, Cramer RA et al (2014) mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 345(6204):1250684CrossRefGoogle Scholar
  14. Cheung NK, Modak S, Vickers A et al (2002) Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother CII 51:557–564PubMedGoogle Scholar
  15. Chihara G, Maeda Y, Hamuro J et al (1969) Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) sing. Nature 222:687–688CrossRefGoogle Scholar
  16. Clynes RA, Towers TL, Presta LG et al (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443–446CrossRefGoogle Scholar
  17. Dai X (2010) Observation on chemotherapy combined with lentinan to treat metaphase or terminal non-small cell lung cancer. J Clin Med Pract 14:73, 77Google Scholar
  18. Dai D (2014) Recent and long-term effect and adverse reaction of lentinan combined with GP chemotherapy in the treatment of non-small cell lung cancer. Mod J Integr Tradit Chin West Med 23:1627–1628Google Scholar
  19. Dai J, Wu W (1998) Regulatory effect of lentinan on immune functions of patients with lung cancer. Cancer Res Prev Treat 25:144–145Google Scholar
  20. Deng M, Wang S, Liu Z (2010) One case of anaphylactic shock induced by lentinan injection. Chin J Drug Appl Monit 07:321–322Google Scholar
  21. Ding N, Huang Z, Zhang Q et al (2012) Observation of clinical effect of lentinan and vinorelbine and cisplatin recombination on patients with advanced non-small cell lung cancer. Anhui Med J 33:681–683Google Scholar
  22. Forman D, Ferlay J (2014) The global and regional burden of cancer. In: Stewart BW, Wild CP (eds) World cancer report 2014. International Agency for Research on Cancer, Lyon, p 16Google Scholar
  23. Gordon M, Bihari B, Goosby E et al (1998) A placebo-controlled trial of the immune modulator, lentinan, in HIV-positive patients: a phase I/II trial. J Med 29:305–330PubMedGoogle Scholar
  24. Hamy AS, Belin L, Bonsang-Kitzis H et al (2018) Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort. Br J Cancer 118:e14CrossRefGoogle Scholar
  25. Han L, Li J, Liu Y (2012) A clinical observation of lentinan combined with GP regimen in patients with advanced non-small cell lung cancer. Her Med 31:1029–1032Google Scholar
  26. He D, Li J, Chen Z (2015) Recent and long-term effect observation of lentinan combined with EP chemotherapy in the treatment of small cell lung cancer. J Huaihai Med 33:598–599Google Scholar
  27. Hirsch FR, Franklin WA, Veve R et al (2002) HER2/neu expression in malignant lung tumors. Semin Oncol 29:51–58CrossRefGoogle Scholar
  28. Ina K, Furuta R (2017) Complete response of metastatic gastric cancer to chemoimmunotherapy. Indian J Med Res 146:141CrossRefGoogle Scholar
  29. Ina K, Furuta R, Kataoka T et al (2011) Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy. World J Clin Oncol 2:339–343CrossRefGoogle Scholar
  30. Ina K, Kataoka T, Ando T (2013) The use of lentinan for treating gastric cancer. Anticancer Agents Med Chem 13:681–688CrossRefGoogle Scholar
  31. Jiang X, Zhou G (2009) Clinical research of combined lentinan for injection with chemotherapy on advanced non-small cell lung cancer. China Mod Dr 47:74–75Google Scholar
  32. Jiang R, Tan X, Liu W et al (2010) Therapeutic effect of combined lentinan, gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer. Med J Qilu 25:132–134Google Scholar
  33. Kay NE, LaPlant BR, Pettinger AM et al (2018) Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia. Expert Rev Hematol 11:337–349CrossRefGoogle Scholar
  34. Kupfahl C, Geginat G, Hof H (2006) Lentinan has a stimulatory effect on innate and adaptive immunity against murine Listeria monocytogenes infection. Int Immunopharmacol 6:686–696CrossRefGoogle Scholar
  35. Levine DB (2008) The Hospital for the Ruptured and Crippled: William Bradley Coley, third Surgeon-in-Chief 1925–1933. HSS J 4:1–9CrossRefGoogle Scholar
  36. Li X (2001) Progress in anti-tumor drugs. China Pharm 12:429–431Google Scholar
  37. Li Z, Zhu Y, Zhang P et al (2009) Clinical observation on GP chemotherapy combined with lentinan to treat advanced non-small cell lung cancer. J Pract Med 25:3480–3482Google Scholar
  38. Li J, Song W, Wang S (2013) 30 cases of advanced non-small cell lung cancer treat with lentinan combined with GP chemotherapy. Guangdong Med J 34:1432–1434Google Scholar
  39. Li C, Zhu T, Lu X (2016) Clinical analysis of the application of lentinus edodes polysaccharides combined with chemotherapy in the treatment of patients with advanced lung cancer. Mod Diagn Treat 27:1614–1616Google Scholar
  40. Liu D, Qian J, Pu M (2003) Research status of anti-tumor effect of lentinan. Edible Fungi 2:6–7Google Scholar
  41. Liu W, Gu J, Qi J et al (2015) Lentinan exerts synergistic apoptotic effects with paclitaxel in A549 cells via activating ROS-TXNIP-NLRP3 inflammasome. J Cell Mol Med 19:1949–1955CrossRefGoogle Scholar
  42. Lu C (2013) Clinical observation on 26 cases of lung cancer with malignant pericardial effusion treated with lentinan and cisplatin. Guiding J Tradit Chin Med Pharm 19:53–54Google Scholar
  43. Lu H, Hong S, Zhang X (2008) Clinical analysis of 63 cases with advanced non-small cell lung cancer treated with lentinan combined with NP chemotherapy. J XinJiang Med Univ 31:92–93Google Scholar
  44. Lv G, Fan L, Zhang Z et al. (2009) Development of research on lentinan. Acta Agriculturae Zhejiangensis 21:183–188Google Scholar
  45. Ma J (2014) Efficacy of lentinan combined with NP regimen in treatment of patients with advanced non-small cell lung cancer and its effect on immunologic function. Chin J Biochem Pharm 34:154–156Google Scholar
  46. Makanjuola SB, Popoola AO, Oludara MA (2014) Radiation therapy: a major factor in the 5-year survival analysis of women with breast cancer in Lagos. Niger Radiother Oncol 111:321–326CrossRefGoogle Scholar
  47. Murphy EA, Davis JM, Carmichael MD (2010) Immune modulating effects of beta-glucan. Curr Opin Clin Nutr Metab Care 13:656–661CrossRefGoogle Scholar
  48. Nishitani Y, Zhang L, Yoshida M et al (2013) Intestinal anti-inflammatory activity of lentinan: influence on IL-8 and TNFR1 expression in intestinal epithelial cells. PLoS One 8:e62441CrossRefGoogle Scholar
  49. Novakovic B, Habibi E, Wang SY et al. (2016) β-Glucan reverses the epigenetic state of LPS-induced immunological tolerance. Cell 167(5):1354–1368CrossRefGoogle Scholar
  50. Peng X, Fan X, Shi X et al (2008) Influence of lentinan on expression of TLR4, TLR9 of mouse splenic T/B cells. Chin J Clin Pharmacol 24:234–236Google Scholar
  51. Peng J, Zhang X, Chen C et al (2013) Nursing care of 3 cases of allergy caused by intravenous infusion of lentinan. Chin Gen Pract Nurs 11:1512Google Scholar
  52. Peter G, Karoly V, Imre B et al (1988) Effects of lentinan on cytotoxic functions of human lymphocytes. Immunopharmacol Immunotoxicol 10:157–163CrossRefGoogle Scholar
  53. Qian J (2010) 34 cases clinical observation of lentinan adjuvant therapy in the treatment of non-small cell lung cancer. Chin J Mod Drug Appl 04:114–115Google Scholar
  54. Quintin J (2018) Fungal mediated innate immune memory, what have we learned? Semin Cell Dev Biol.  https://doi.org/10.1016/j.semcdb.2018.05.023 CrossRefPubMedGoogle Scholar
  55. Quintin J, Saeed S, Martens JHA et al (2012) Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe 12:223–232CrossRefGoogle Scholar
  56. Ruthes AC, Smiderle FR, Iacomini M (2016) Mushroom heteropolysaccharides: a review on their sources, structure and biological effects. Carbohyd Polym 136:358–375CrossRefGoogle Scholar
  57. Saitô H, Ohki T, Takasuka N et al (1977) A 13C-N.M.R.-Spectral study of a gel-forming, branched (1 → 3)-β-d-glucan, (lentinan) from Lentinus edodes, and its acid-degraded fractions. Structure, and dependence of conformation on the molecular weight. Carbohyd Res 58:293–305CrossRefGoogle Scholar
  58. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl J Med 346:92–98CrossRefGoogle Scholar
  59. Shang S, Huang J (2009) Observation on short-term therapeutic and adverse effect of lentinan and vinorelbine and oxaliplatin in recombination on patients with advanced non-small cell lung cancer. Clin Focus 24:501–504Google Scholar
  60. Shi X, Ding Q, Yang Q (2007) Lentinan combined with chemotherapy in the treatment of advanced non-small cell lung cancer. China Cancer 16:946–948Google Scholar
  61. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York, NY) 235:177–182CrossRefGoogle Scholar
  62. Song Q, Zhu J (2016) Effect of Mushroom polysaccharide injection on serum tumor markers and clinical effect in patients with stage III and IV SCLC. J China Prescr Drug 14:12–13Google Scholar
  63. Surenjav U, Zhang L, Xu X et al (2006) Effects of molecular structure on antitumor activities of (1 → 3)-β-d-glucans from different Lentinus edodes. Carbohyd Polym 63:97–104CrossRefGoogle Scholar
  64. The Top 10 Causes of Death (2018). http://www.who.int/mediacentre/factsheets/fs310/en/. Accessed 23 July 2018
  65. Thomas AA, Brennan CW, DeAngelis LM et al (2014) Emerging therapies for glioblastoma. JAMA Neurol 71:1437–1444CrossRefGoogle Scholar
  66. van Meir H, Nout RA, Welters MJ et al (2017) Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients. Oncoimmunology 6:e1267095CrossRefGoogle Scholar
  67. Wang J (1994) Clinical observation of lentinan in treatment of 60 cases of hepatitis B. J Chin Med 16:23–24Google Scholar
  68. Wang W, Dai X, Ouyang X (2006) Efficacy of lentinan combined with chemotherapy in advanced non-small cell lung cancer. China J Lung Cancer 09:78–81Google Scholar
  69. Wang G, Lin W, Zhao R et al (2008) Effects of six polysaccharides extracted from plants on the immunological cells of mice. J Hyg Res 37:577–580Google Scholar
  70. Wang J, Dong S, Liu C et al (2010) β-Glucan oligosaccharide enhances CD8(+) T cells immune response induced by a DNA vaccine encoding hepatitis B virus core antigen. J Biomed Biotechnol 2010:645213PubMedPubMedCentralGoogle Scholar
  71. Wang J, Zhang Y, Zhao H (2011) The influence of immune functions and therapeutic and adverse effect of lentinan combined with chemotherapy in advanced non-small cell lung cancer. Natl Med Front China 06:15–17Google Scholar
  72. Wang JL, Bi Z, Zou JW et al (2012) Combination therapy with lentinan improves outcomes in patients with esophageal carcinoma. Mol Med Rep 5:745–748CrossRefGoogle Scholar
  73. Wang Y, Han X, Li YD et al (2015) Effects of tumor-specific antigen induced by lentinan on murine H22 hepatocellular carcinoma immunoprophylaxis. Eur Rev Med Pharmacol Sci 19:4516–4524PubMedGoogle Scholar
  74. Wang P, Zhao S, Yang B et al (2016) Anti-diabetic polysaccharides from natural sources: a review. Carbohyd Polym 148:86–97CrossRefGoogle Scholar
  75. Wei Y, Xie M (2015) The influence of lentinan injection on curative effect and quality life of patients with medium and advanced lung cancer after chemotherapy. Guiding J Tradit Chin Med Pharm 21:25–27Google Scholar
  76. Wu X (2009) Clinical observation on advanced non-small cell lung cancer in the old treated with lentinan combined with NVB and DDP. China Foreign Med Treat 28:76–77Google Scholar
  77. Wu X (2015) Clinical analysis of lentinan combined with chemotherapy in treatment of advanced lung cancer. Chin Arch Tradit Chin Med 27:456–458Google Scholar
  78. Wu B, Zhang Y, Zhang L (1993) III clinical trial summary of lentinan in the treatment of 108 cases with chronic viral hepatitis. Fujian J Tradit Chin Med 24:10–13, 50Google Scholar
  79. Xiao X, Liu C, Yuan X et al (2015) Clinical effect of lentinan combined with DP chemotherapy on middle-late stage non-small cell lung cancer. Pract J Card Cereb Pneumal Vasc Dis 23:91–93Google Scholar
  80. Xie Z, Xie J, Wen J et al (2006) A comparison between TP regimen with lentinan and with megestrol acetate for advanced non-small cell lung cancer. China Cancer 15:199–202Google Scholar
  81. Xin W, Shi L, Zhou Y (2016) Efficacy of lentinan combined with NP chemotherapy in treatment of patients with advanced non-small cell lung cancer and its effect on immunologic function. Mod J Integr Tradit Chin West Med 25:3349–3351Google Scholar
  82. Xu X, Pan C, Zhang L et al (2011) Immunomodulatory beta-glucan from Lentinus edodes activates mitogen-activated protein kinases and nuclear factor-kappaB in murine RAW 264.7 macrophages. J Biol Chem 286:31194–31198CrossRefGoogle Scholar
  83. Yin H, Yang G (2016) Efficacy of synergistic combination of lentinan and GP regimen in stage IV lung squamous cell carcinoma. Oncol Prog 14:687–689Google Scholar
  84. Yoshino S, Tabata T, Hazama S et al (2000) Immunoregulatory effects of the antitumor polysaccharide lentinan on Th1/Th2 balance in patients with digestive cancers. Anticancer Res 20:4707–4711PubMedGoogle Scholar
  85. Yoshino S, Yoshida S, Maeda N et al (2010) Clinical evaluation of the combination treatment of intrapleural or intraperitoneal administration of lentinan and OK-432 for malignant effusion. Gan to kagaku ryoho. Cancer Chemother 37:2798–2800Google Scholar
  86. Yue F, Jia T (2010) Clinical observation of lentinan combined with paclitaxel liposome on advanced non-small cell lung cancer. Pract J Card Cereb Pneumal Vasc Dis 18:1791–1792Google Scholar
  87. Zhang H (2016) Clinical analysis of lentinan combined with chemotherapy for elderly patients with advanced non-small cell lung cancer. Shenzhen J Integr Tradit Chin West Med 26:44–45Google Scholar
  88. Zhang H, Xu J, Ren S (2009) Lentinan combined with chemotherapy in treatment of advanced non-small cell lung cancer. Chin J Cancer Biother 16:523–525Google Scholar
  89. Zhang C, Xie C, Kang Z et al (2014) Clinical observation on GP chemotherapy combined with lentinan to treat metaphase or terminal non-small cell lung cancer. J Qiqihar Univ Med 35:164–165Google Scholar
  90. Zhang Y, Li Q, Shu Y et al (2015a) Induction of apoptosis in S180 tumour bearing mice by polysaccharide from Lentinus edodes via mitochondria apoptotic pathway. J Funct Foods 15:151–159CrossRefGoogle Scholar
  91. Zhang Y, Yu J, Xiang Y et al (2015b) Clinical efficacy and safety of lentinan combined with chemotherapy for elderly patients with advanced non-small cell lung cancer. Antitumor Pharm 03:222–225Google Scholar
  92. Zhao L (2012) A clinical study on non-small cell lung cancer therapy by combination of lentinan with chemotherapy. Anhui Med Pharm J 16:1496–1497Google Scholar
  93. Zhao X, Ma L (2011) Toxicity-reducing and efficacy-enhancing action of lentinan with chemotherapy in the treatment of advanced non-small cell lung cancer. Clin Ration Drug Use 04:20–21Google Scholar
  94. Zhao C, Li X, Wang Z et al (2011) Immune function and effect of concurrent chemoradiotherapy combined lentinan on patients with advanced non-small cell lung cancer. Anhui Med Pharm J 15:1431–1433Google Scholar
  95. Zhao W, Chen D, Chen J (2013) Curative effect and adverse reaction of lentinan combined with gemcitabine and cisplatin in the treatment of non-small cell lung cancer. Chin J Clin Pharmacol Ther 18:71–77Google Scholar
  96. Zheng H, Zeltsman M, Zauderer MG et al (2017) Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. Immunotherapy 9:913–927CrossRefGoogle Scholar
  97. Zhou C, Liu M (2010) 30 cases of adverse reaction caused by lentinan. Zhejiang J Integr Tradit Chin West Med 20:635Google Scholar
  98. Zhou Z, Han Z, Zeng Y et al (2014) Chinese FDA approved fungal glycan-based drugs: an overview of structures, mechanisms and clinical related studies. Transl Med 04:1000141Google Scholar
  99. Zhu Y, Zhang L (2013) Short-term curative effect of lentinan combined with chemotherapy in the treatment of lung cancer and its evaluation of immune function. China Pract Med 08:156–157Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Yiran Zhang
    • 1
  • Meng Zhang
    • 1
  • Yifei Jiang
    • 1
    • 2
  • Xiulian Li
    • 1
    • 2
  • Yanli He
    • 1
    • 2
  • Pengjiao Zeng
    • 1
  • Zhihua Guo
    • 2
  • Yajing Chang
    • 1
    • 2
  • Heng Luo
    • 1
    • 2
  • Yong Liu
    • 1
    • 2
  • Cui Hao
    • 1
  • Hua Wang
    • 1
  • Guoqing Zhang
    • 1
  • Lijuan Zhang
    • 1
  1. 1.Systems Biology and Medicine Center for Complex DiseasesAffiliated Hospital of Qingdao UniversityQingdaoChina
  2. 2.School of Medicine and PharmacyOcean University of ChinaQingdaoChina

Personalised recommendations